Literature DB >> 7651727

Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.

W V Kastrinakis1, N Ramchurren, K M Rieger, D T Hess, M Loda, G Steele, I C Summerhayes.   

Abstract

Within a panel of 15 colon carcinoma cell lines we have characterized the p53 gene status using immunocytochemistry (ICC), SSCP and direct sequence analysis. Extension of this analysis to the use of ICC on 104 colonic lesions, representative of different stages of colonic neoplastic progression, showed an absence of detectable p53 nuclear staining in preneoplastic polyp lesions (20 cases) with staining of 52% (25/48) of primary colon carcinomas and 81% (29/36) of hepatic metastases, suggestive of an increased incidence of p53 mutations in late stage lesions of colonic cancer. To address this issue more directly, we analysed 18 primary colon carcinomas and hepatic metastases excised coincidentally from the same patients. In ICC, p53 nuclear staining was recorded in matching lesions from eight individuals where direct sequencing revealed identical mutations in each case. In four individuals no ICC staining was detected in either lesion and molecular analysis revealed wild type sequence in exons 4-9. In six individuals p53 nuclear staining was observed in the hepatic metastases of patients but not the primary lesion. Molecular analysis revealed point mutation events in hepatic metastases from these patients which were not detected in the primary tumor. The point mutations identified in colon carcinomas were predominantly transition events (83%) located in previously characterized colon hotspot regions. These results demonstrate an increased incidence of p53 mutations associated with secondary lesions of colorectal tumors suggestive of a role for p53 in the establishment of colorectal hepatic metastases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7651727

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.

Authors:  M Loda; P Capodieci; R Mishra; H Yao; C Corless; W Grigioni; Y Wang; C Magi-Galluzzi; P J Stork
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 2.  The two faces of tumor suppressor p53.

Authors:  M L Smith; A J Fornace
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 3.  What we could do now: molecular pathology of colorectal cancer.

Authors:  R S Houlston
Journal:  Mol Pathol       Date:  2001-08

4.  Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Authors:  David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2019-08-30       Impact factor: 7.842

Review 5.  Meeting the biologic challenge of colorectal metastases.

Authors:  Harold J Wanebo; Mark LeGolvan; Philip B Paty; Sukamal Saha; Markus Zuber; Michael I D'Angelica; Nancey E Kemeny
Journal:  Clin Exp Metastasis       Date:  2012-10-10       Impact factor: 5.150

6.  Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas.

Authors:  P Kanavaros; K Stefanaki; K Valassiadou; J Vlachonikolis; M Mavromanolakis; M Vlychou; S Kakolyris; V Gorgoulis; M Tzardi; V Georgoulias
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

7.  Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.

Authors:  Zhong-Zheng Zhu; Bing Liu; Ai-Zhong Wang; Hang-Ruo Jia; Xia-Xiang Jin; Xiang-Lei He; Li-Fang Hou; Guan-Shan Zhu
Journal:  J Zhejiang Univ Sci B       Date:  2008-11       Impact factor: 3.066

8.  Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras, and p53 genes.

Authors:  Jy-Ming Chiang; Yah-Huei Wu Chou; Shih-Chieh Ma; Jim-Ray Chen
Journal:  Virchows Arch       Date:  2004-09-24       Impact factor: 4.064

9.  Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.

Authors:  Mirna Lechpammer; Josip Lukac; Stanislav Lechpammer; Dujo Kovacević; Massimo Loda; Zvonko Kusić
Journal:  Int J Colorectal Dis       Date:  2003-11-21       Impact factor: 2.571

10.  Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases.

Authors:  A Russo; M Migliavacca; V Bazan; N Maturi; V Morello; G Dardanoni; G Modica; P Bazan; I Albanese; M La Farina; R M Tomasino
Journal:  Cell Prolif       Date:  1998 Jun-Aug       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.